Loading clinical trials...
Loading clinical trials...
A Phase II, Single Center, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
Conditions
Interventions
MenACWY-CRM
DTaP-Hib-IPV
+3 more
Locations
1
United Kingdom
Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine
Headington, Oxford, United Kingdom
Start Date
July 1, 2007
Primary Completion Date
May 1, 2009
Completion Date
June 1, 2009
Last Updated
October 1, 2014
NCT01725217
NCT03694405
NCT04358731
NCT01896596
NCT02811120
NCT03089086
Lead Sponsor
Novartis Vaccines
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions